Swedish Orphan Biovitrum SOBI.SE | STOCKHOLM Exch | Medical-Biomed/Biotech | MktCap SEK113.56B Sales SEK23.71B | Shares 356M Float 178M | EPS Due in 31 Days (e)

4686972000 sobi.com Solna, SWEDEN Inc 2001 MGMT owns --
EPS Rank 36

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden. LESS

ANNUAL - DEC END	2015	2016	2017	2018	2019	2020	2021	2022	2023
EPS SEK	0.23	2.86	4.08	8.57	10.78	10.52	8.67	8.52	7.47
CASH FLOW/SHR SEK	1.81	1.22	4.72	7.38	11.79	16.73	17.60	14.93	13.71
PRETAX MARGIN %	3%	20%	24%	34%	30%	28%	21%	18%	13%
RETURN ON EQUITY %	1%	16%	19%	31%	25%	18%	12%	11%	8%
SALES % CHANGE	24%	61%	25%	40%	56%	7%	2%	21%	18%
SALES (MIL) SEK	3,228	5,204	6,511	9,139	14K	15K	16K	19K	22K

WEEKLY	Jul 26	Aug 2	Aug 9	Aug 16	Aug 23	Aug 30	Sep 6	Sep 13	Sep 20
DATAGRAPH RATING	55	54	54	60	59	63	55	62	60
AVG DAILY VOL (000)	316	310	329	334	335	349	345	351	402
UP DOWN VOLUME	1.5	1.5	1.7	1.7	1.9	2.0	1.8	2.0	1.5
ACCUM/DIST RATING	2	-16	2	33	24	33	34	38	19
RELATIVE STRENGTH	68	60	65	81	74	77	78	82	79
GROUP RANK	67	65	54	31	35	31	37	28	21

2024 Estimate	2025 Estimate
9.66 29%	14.83 54%

Earnings Growth Rate	Sales Growth Rate
2022-24 -8% (13 Stability)	18%
2020-24 -6% (13 Stability)	13%

COMP RATING 83 SMR RATING A
INV T/O 2.2x 46

DEBT %	2021-23	39%	12%	34%
TAX RATE	2021-23	19%	21%	18%
BACKLOG	2021-23	--	--	--

R & D 12.30% BK VAL 3.20x '23
DIV SEK None DIV GR RT--
BETA 0.58(7.00) ALPHA 0.12 (0.07)
2023 EMPLOYEES 1,772 (14%)





FINANCIALS	Sep 20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
EPS (SEK)	0.90	4.87	2.26	0.87	1.53	4.02	1.76	0.83	1.46	4.47	3.44	0.71	0.30	3.02	2.35	0.66	2.14e	4.11e	3.86e	3.18e
EPS % CHANGE	-49%	+10%	-41%	-5%	+70%	-17%	-22%	-5%	-5%	+11%	+95%	-14%	-79%	-32%	-32%	-7%	+613%e	+36%e	+64%e	+382%e
SALES (MIL SEK)	2,970.0	4,581.0	3,661.0	3,211.0	3,761.0	4,896.0	4,925.0	3,876.0	3,999.0	5,991.0	5,239.0	4,872.0	5,168.0	6,844.0	6,256.0	5,442.0	6,006.7e	7,225.6e	6,694.0e	6,298.0e
SALES % CHANGE	+1%	-6%	-21%	+5%	+27%	+7%	+35%	+21%	+6%	+22%	+6%	+26%	+29%	+14%	+19%	+12%	+16%e	+6%e	+7%e	+16%e
EPS % SURPRISE	-10.6%	+15.4%	-9.5%	+39.1%	+4.3%	+23.5%	+27.8%	+15.3%	+10.1%	+6.0%	+5.9%	+39.0%	+46.7%	-15.7%	+0.3%	-13.6%				
FUNDS	395	376	366	340	311	267	300	591	705	787	807	839	836	880	949	929				
SHARES HELD BY FUNDS	89M	69M	66M	58M	48M	38M	48M	62M	66M	66M	67M	66M	75M	89M	95M	96M				

P/E	50
2024 Est.:	33.0
2025 Est.:	21.5
5-yr High:	47
5-yr Low:	11
vs Ind. Avg:	

PANARAY® 2024 WILLIAM O'NEIL + CO. INC.